Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram

Published:2024-09 Issue: Volume:261 Page:155504
ISSN:0344-0338
Container-title:Pathology - Research and Practice
language:en
Short-container-title:Pathology - Research and Practice

Author:

Jia Zhanli,Xing Hui,Wang Jian,Wang Xinran,Wang Xu,Liu Chang,He Jiankun,Wu Si,Miao Jiaxian,Liu Hongbo,Liu Yueping

Publisher

Elsevier BV

Reference32 articles.

1. Adjuvant and neoadjuvant therapy for breast cancer;Shien;Jpn J. Clin. Oncol.,2020

2. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden;Asano;BMC Cancer,2017

3. Molecular testing in breast cancer: a guide to current practices;Hagemann;Arch. Pathol. Lab Med.,2016

4. Treatment of advanced HER2-positive breast cancer: 2018 and beyond;Pondé;Cancer Treat. Rev.,2018

5. Breast cancer recurrence according to molecular subtype;Shim;Asian Pac. J. Cancer Prev.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP